7068 results for
Refine Your Search
Deciphering the interplay between apoptotic and signaling pathways to target T-lineage acute lymphoblastic leukemia
T-ALL is an aggressive leukemia with limited treatment options. T-ALL cells resist to dying by suppressing their suicide pathways. BH3 mimetics reacti…
Sigurður Kristinsson
Professor Sigurður Yngvi Kristinsson is currently consolidating his position as one of the leading researchers world-wide in the field of multiple mye…
Early Detection and Intervention in Smoldering Multiple Myeloma: population-based screening and treatment; Edit-SMM
We build on the success from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study, where over 80,000 consented to a nationwide sc…
Nitin Jain
Nitin Jain, MD, is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center in Houston. He earned his medical degree from the…
Combination Targeted Therapy in Chronic Lymphocytic Leukemia
Targeted therapies have replaced chemoimmunotherapy in chronic lymphocytic leukemia (CLL). We previously reported that combined BTK inhibitor (ibrutin…
Nirav Shah
Nirav Shah, MD, MSHP is currently an Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, special…
Improving Bispecific CD20/CD19 CAR T-cell Therapy to Overcome Resistance Mechanisms in B-cell Malignancies
The objective of this proposal is to improve bispecific anti-CD20/anti-CD19 CAR T-cell activity and persistence by understanding impact of cell manufa…
Neha Mehta-Shah
Neha Mehta-Shah, MD, MSCI is an Assistant Professor of Medicine at Washington University in St. Louis where she specializes in peripheral and cutaneou…
Predictors of response to therapy in A051902, a US Intergroup study of duvelisib+CHO(E)P vs CC-486+CHO(E)P vs CHO(E)P in peripheral T-cell lymphoma
We are evaluating if adding duvelisib or azacitidine to standard chemotherapy increases the complete remission rate compared to chemotherapy alone in …
Tycel Phillips
I am a physician employed at the University of Michigan who specializes in the management of patients with a very specific blood cancer called lymphom…
Stratified treatment of newly diagnosed MCL based on the presence or absence of high risk features utilizing non-cytotoxic agents.
We believe that regimens without chemotherapy can induce significant and durable remissions in patients with Mantle cell lymphoma (MCL). We will confi…
Thomas LeBlanc
I am a board-certified oncologist and palliative care physician, Associate Professor of Medicine in the Duke University School of Medicine, and member…
Patient Experience Research and Palliative Care Integration in Malignant Hematology
My research aims to improve the patient and caregiver experience of blood cancer care. To achieve this, I conduct trials of integrated palliative care…
Understanding the clonal origin, evolution, and progression of myeloid malignancies
The overarching focus of my research is to understand the clonal origin, evolution, and progression of myeloid malignancies and biological and clinica…
Koichi Takahashi
Koichi Takahashi, MD, PhD is Associate Professor in the Departments of Leukemia and Genomic Medicine at The University of Texas MD Anderson Cancer Cen…
Luca Busino
The molecular mechanisms of cell proliferation and the field of Ubiquitin Proteasome System (UPS) have always been our main area of interest and fasci…
Relevance of ubiquitin dependent proteolysis in Diffuse Large B-cell lymphoma
The goal of this proposal is to investigate the significance of genes of the ubiquitin proteasome system (UPS) that are mutated in Diffuse Large B-cel…
Paul
I have been very active with LLS for over 17 years including: serving on the Wisconsin Chapter Board and Leadership Development Committee; fundraising…
Living with Myeloma
Coleman Lindsley
Dr. Lindsley is an Assistant Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute. He received his M.D. and Ph.D.
Genetic pathways of myeloid transformation and treatment response
Our central goal is to improve clinical outcomes in patients with myeloid malignancies through developing an enhanced mechanistic understanding of dis…
Julia Maxson
Dr. Maxson is an assistant professor in the Knight Cancer Institute, where she investigates the cellular and molecular changes that cause myeloid leuk…
Targeting the interplay between signaling and transcriptional dysfunction in myeloid leukemias
Our research program is focused on understanding the intersection between signaling and transcriptional dysfunction in myeloid leukemias. We leverage …
Yibin Yang
I completed my Ph.D. training with Dr. Michelle Kelliher at the University of Massachusetts Medical School, studying the ubiquitin-dependent signal tr…
Analysis and therapeutic targeting of the immune regulatory and ubiquitination pathways in Anaplastic Large Cell Lymphoma and Hodgkin Lymphoma
My lab is focused on the immune regulatory mechanisms and ubiquitin-dependent machinery in lymphoma. We have established multiple high-throughput scre…
Genomic interrogation of high-risk myeloid neoplasms to identify new therapies
The long-term goal of my research program is to improve the outcomes for patients with high-risk myeloid blood cancers, particularly those with loss o…